Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SVMI gonna go BOOM soon.
SVMI volume picking up. Moving strong.
SVMI KABOOM. Starting next leg.
SVMI looks great. Accumulating.
Read through the PR's released by PFSD over the past few months. Major marketing campaign set to launch in May. I've used the hot tub chemicals for many years and they work great.
http://www.pacificsands.biz/html/investor_relations.html
I was hoping for a big dip, but it appears to be gaining strength.
XKEM is a strong buy anywhere under .015 IMO.
XKEM annotated chart and opinion
XKEM is breaking out of its down triangle. Todays close showed stength holding above its support pivot (also 200DMA). By next week this could get exciting.
Good time to start accumulating.
If the .03 neck line of the inverted head and shoulders is taken out, this will signal a MAJOR trend reversal and will be a ride to remember.
XKEM annotated chart and opinion
XKEM is breaking out of its down triangle. Todays close showed stength holding above its support pivot (also 200DMA). By next week this could get exciting.
Good time to start accumulating.
If the .03 neck line of the inverted head and shoulders is taken out, this will signal a MAJOR trend reversal and will be a ride to remember.
CLBE staging for a launch soon.
PFSD 2 year chart
CLBE golden cross chart. Volume increasing
CLBE Golden cross breakout.....
CLBE closing gap then it should run.
FPPL Bid stacking. Gonna move up soon IMO
FPPL bottomed here IMO. Strong buy
FPPL bottomed here IMO. Strong buy
CLBE golden cross chart......
CalbaTech Announces Significant Revenue Increase in 2005; Forecasts Profitability in 2006 and Expects to See Continued Progress by Its Subsidiary LifeStem With Its Stem Cell Microbank(TM) Service
Apr 3, 2006 7:40:00 PM
IRVINE, Calif., April 3 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the biotech and pharmaceutical research market and to academic institutions, today announced revenues for the fiscal year ended December 31, 2005 totaled $1.292 million, up 430 percent from revenues of $300,633 in 2004.
The Company's Reagents Division, had revenues of $1.292 million in 2005. CalbaTech said it projects these revenues will increase to $5 million within three years.
"We have streamlined expenses and combined marketing in the Reagents Division, resulting in that Division being profitable in 2005. Additionally, we are confident that with lower overhead and the new, state-of-the-art ISO 9002 certified compliant facility, which features two class 100 clean rooms, we will see a consistently profitable record of growth. This will allow both for expanded product lines, and contract manufacturing and leasing opportunities," said James DeOlden, CalbaTech Chairman and CEO.
The Company announced a net loss for the year of $5 million, incurring an unrealized one-time loss in recording the fair value of the debenture and related warrant derivatives relating to the convertible notes it obtained in 2005. The total non-cash financial impact to CalbaTech's income statement amounted to $2.3 million and the Company also incurred non-cash interest costs of $916,232 relating to the convertible debt accretion. CalbaTech said it anticipates realizing a gain of $4.15 million pursuant to this one-time loss in the year ending 2006.
CalbaTech said it expects significant progress in 2006 by its wholly own subsidiary, LifeStem, and its Stem Cell Microbank(TM) Service, which collects and stores healthy adult stem cells for autologous use.
"The therapeutic possibilities for use of these stem cells in curing diseases are potentially limitless. Our focus is on refining existing collection processes and storing stem cell samples from two tissue sources," Mr. DeOlden said. "We are the only Company that is collecting and storing adult stem cells from two different cell sources and we expect to begin generating revenue from these collections by LifeStem in the second quarter of 2006."
Finally, CalbaTech said its Form 10-KSB was filed on March 31, 2006, within the prescribed time period, and it will file a statement showing that its filing should revert to that date. Problems with the Federal Government's EDGAR filing system occurred on March 31.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Contact:
Paul Knopick
E&E Communications
(949) 707-5365
pknopick@eandecommunications.com
Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to being in a large and growing market, exhibiting rapid growth characteristics, and having a growth strategy, are forward looking statements. These forward looking statements are only predictions and are subject to certain risks, uncertainties and assumptions. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or assumptions in this press release include the risk that we will not be able to grow our revenues and market share, the risk that our prices do not remain competitive and the risk that we will not achieve profitability. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission, including our most recent Report on Form 10-KSB, and Reports on Form 10-QSB and Form 8-K. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
SOURCE CalbaTech, Inc.
----------------------------------------------
Paul Knopick of E&E Communications
+1-949-707-5365
pknopick@eandecommunications.com
for CalbaTech
Inc.
CLBE moving on record revenue news
CLBE volume starting to pick up
CalbaTech Announces Significant Revenue Increase in 2005; Forecasts Profitability in 2006 and Expects to See Continued Progress by Its Subsidiary LifeStem With Its Stem Cell Microbank(TM) Service
Apr 3, 2006 7:40:00 PM
IRVINE, Calif., April 3 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the biotech and pharmaceutical research market and to academic institutions, today announced revenues for the fiscal year ended December 31, 2005 totaled $1.292 million, up 430 percent from revenues of $300,633 in 2004.
The Company's Reagents Division, had revenues of $1.292 million in 2005. CalbaTech said it projects these revenues will increase to $5 million within three years.
"We have streamlined expenses and combined marketing in the Reagents Division, resulting in that Division being profitable in 2005. Additionally, we are confident that with lower overhead and the new, state-of-the-art ISO 9002 certified compliant facility, which features two class 100 clean rooms, we will see a consistently profitable record of growth. This will allow both for expanded product lines, and contract manufacturing and leasing opportunities," said James DeOlden, CalbaTech Chairman and CEO.
The Company announced a net loss for the year of $5 million, incurring an unrealized one-time loss in recording the fair value of the debenture and related warrant derivatives relating to the convertible notes it obtained in 2005. The total non-cash financial impact to CalbaTech's income statement amounted to $2.3 million and the Company also incurred non-cash interest costs of $916,232 relating to the convertible debt accretion. CalbaTech said it anticipates realizing a gain of $4.15 million pursuant to this one-time loss in the year ending 2006.
CalbaTech said it expects significant progress in 2006 by its wholly own subsidiary, LifeStem, and its Stem Cell Microbank(TM) Service, which collects and stores healthy adult stem cells for autologous use.
"The therapeutic possibilities for use of these stem cells in curing diseases are potentially limitless. Our focus is on refining existing collection processes and storing stem cell samples from two tissue sources," Mr. DeOlden said. "We are the only Company that is collecting and storing adult stem cells from two different cell sources and we expect to begin generating revenue from these collections by LifeStem in the second quarter of 2006."
Finally, CalbaTech said its Form 10-KSB was filed on March 31, 2006, within the prescribed time period, and it will file a statement showing that its filing should revert to that date. Problems with the Federal Government's EDGAR filing system occurred on March 31.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Contact:
Paul Knopick
E&E Communications
(949) 707-5365
pknopick@eandecommunications.com
Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to being in a large and growing market, exhibiting rapid growth characteristics, and having a growth strategy, are forward looking statements. These forward looking statements are only predictions and are subject to certain risks, uncertainties and assumptions. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or assumptions in this press release include the risk that we will not be able to grow our revenues and market share, the risk that our prices do not remain competitive and the risk that we will not achieve profitability. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission, including our most recent Report on Form 10-KSB, and Reports on Form 10-QSB and Form 8-K. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
SOURCE CalbaTech, Inc.
----------------------------------------------
Paul Knopick of E&E Communications
+1-949-707-5365
pknopick@eandecommunications.com
for CalbaTech
Inc.
CalbaTech Announces Significant Revenue Increase in 2005; Forecasts Profitability in 2006 and Expects to See Continued Progress by Its Subsidiary LifeStem With Its Stem Cell Microbank(TM) Service
Apr 3, 2006 7:40:00 PM
IRVINE, Calif., April 3 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the biotech and pharmaceutical research market and to academic institutions, today announced revenues for the fiscal year ended December 31, 2005 totaled $1.292 million, up 430 percent from revenues of $300,633 in 2004.
The Company's Reagents Division, had revenues of $1.292 million in 2005. CalbaTech said it projects these revenues will increase to $5 million within three years.
"We have streamlined expenses and combined marketing in the Reagents Division, resulting in that Division being profitable in 2005. Additionally, we are confident that with lower overhead and the new, state-of-the-art ISO 9002 certified compliant facility, which features two class 100 clean rooms, we will see a consistently profitable record of growth. This will allow both for expanded product lines, and contract manufacturing and leasing opportunities," said James DeOlden, CalbaTech Chairman and CEO.
The Company announced a net loss for the year of $5 million, incurring an unrealized one-time loss in recording the fair value of the debenture and related warrant derivatives relating to the convertible notes it obtained in 2005. The total non-cash financial impact to CalbaTech's income statement amounted to $2.3 million and the Company also incurred non-cash interest costs of $916,232 relating to the convertible debt accretion. CalbaTech said it anticipates realizing a gain of $4.15 million pursuant to this one-time loss in the year ending 2006.
CalbaTech said it expects significant progress in 2006 by its wholly own subsidiary, LifeStem, and its Stem Cell Microbank(TM) Service, which collects and stores healthy adult stem cells for autologous use.
"The therapeutic possibilities for use of these stem cells in curing diseases are potentially limitless. Our focus is on refining existing collection processes and storing stem cell samples from two tissue sources," Mr. DeOlden said. "We are the only Company that is collecting and storing adult stem cells from two different cell sources and we expect to begin generating revenue from these collections by LifeStem in the second quarter of 2006."
Finally, CalbaTech said its Form 10-KSB was filed on March 31, 2006, within the prescribed time period, and it will file a statement showing that its filing should revert to that date. Problems with the Federal Government's EDGAR filing system occurred on March 31.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Contact:
Paul Knopick
E&E Communications
(949) 707-5365
pknopick@eandecommunications.com
Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to being in a large and growing market, exhibiting rapid growth characteristics, and having a growth strategy, are forward looking statements. These forward looking statements are only predictions and are subject to certain risks, uncertainties and assumptions. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or assumptions in this press release include the risk that we will not be able to grow our revenues and market share, the risk that our prices do not remain competitive and the risk that we will not achieve profitability. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission, including our most recent Report on Form 10-KSB, and Reports on Form 10-QSB and Form 8-K. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
SOURCE CalbaTech, Inc.
----------------------------------------------
Paul Knopick of E&E Communications
+1-949-707-5365
pknopick@eandecommunications.com
for CalbaTech
Inc.
FPPL buy volume picking up.
CNES moving up. FPPL chart is primed for major move.
Agreed, PAPO, FPPL and other energy stocks are $$$$$$$$$$$
FPPL = sweet chart!
Wow FPPL chart is sweet!
PAPO gonna pop here.
PAPO gonna rally again here.
PAPO KABOOM!
PAPO moving up strong.
CNES gonna charge through .0015 soon. Then KABOOM
CNES gonna run hard IMO.
CNES lookin good for a breakout here.
AVST 1 MM till .018. MM's backing way off the Ask.
Yep there is 1 MM till .018 on AVST.
AVST chart looks sweet.
AVST kaboom! MOMO Time!
AVST moving up strong pre market
CLBE golden cross breakout week. Volume started coming in late friday and it broke the 200DMA. Multibagger soon IMO.